Effects of Bezafibrate on Lipid and glucose metabolism in dyslipidemic patients with impaired glucose tolerance - Comparative analysis of the characteristics of dyslipidemia improving drugs for postprandial metabolic disorder.-

Effects of Bezafibrate on Lipid and glucose metabolism in dyslipidemic patients with impaired glucose tolerance - Comparative analysis of the characteristics of dyslipidemia improving drugs for postprandial metabolic disorder.- - BRILLIANT study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008157

Enrollment

Registered

2012-06-13

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with metabolic syndrome

Interventions

Participants in the bezafibrate treatment group will be received 400mg/day of bezafibrate during 3 months. If a patient&#39

s consent is obtained, the treatmentwill be continued for more 3 months. Participants in the atrovastatin treatment group will be received 10mg/day of atrovastatin during 3months. If a patient&#39

s consent is obtained, the treatment will be continued vfor more 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have metabolic syndrome according to IDF definition without history of coronary heart disease. 2) Patients who have triglyceride levels of 150mg/dL or higher and have LDL cholesterol levels of 120mg/dL or higher after an overnight fasting. 3) Patients who give informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have contraindication of bezafibrate or atrovastatin treatment. 2) Patients who have taken any lipid-lowering drug within one month. 3) Patient who have taken any antidaibetic agents. 4) Alcoholic patients. 5) Patients judged to be unsuitable participants by physician-in-charge

Design outcomes

Primary

Measure	Time frame
1) Levels of triglycerides, HDL-cholesterol, total cholesterol and LDL-cholesterol 2) Diameter of lipoproteins measured by HPLC 3)HbA1c (NGSP) and 75g OGTT (glucose and insulin levels at 0, 30, 60 and 120 min after glucose load) 4)Safety (Adverse effects including hypoglycemia, body weigh gain)	—

Secondary

Measure	Time frame
1)MDA-LDL levels and MDA-LDL/LDL cholesterol 2)Insulin sensitivity (HOMA-IR, QUICKI) 3)Plasma adiponectin levels 4)Plasma high sensitive C reactive protein levels 5)Body weight, body mass index (BMI) and blood pressure 6)Renal function and liver function tests	—

Countries

Japan

Contacts

Public ContactKazunori Shimada

Juntendo University Hospital Department of Cardiovascular Medicine

shimakaz@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026